At our department, TERT promoter mutational screening for FT-UMPs was introduced in 2014 as a standardized part of the pathology work-up in the diagnostic process, and the occurrence of a mutational event was noted in the patient charts, with each case discussed at a weekly, multi-disciplinary tumor board conference. The gene discussed is TERT; the disease is neoplasm.